These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 26171232)

  • 1. Increased efficacy of VX-809 in different cellular systems results from an early stabilization effect of F508del-CFTR.
    Farinha CM; Sousa M; Canato S; Schmidt A; Uliyakina I; Amaral MD
    Pharmacol Res Perspect; 2015 Aug; 3(4):e00152. PubMed ID: 26171232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measurements of Functional Responses in Human Primary Lung Cells as a Basis for Personalized Therapy for Cystic Fibrosis.
    Awatade NT; Uliyakina I; Farinha CM; Clarke LA; Mendes K; Solé A; Pastor J; Ramos MM; Amaral MD
    EBioMedicine; 2015; 2(2):147-53. PubMed ID: 26137539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of 6,9-dihydro-5H-pyrrolo[3,2-h]quinazolines as a new class of F508del-CFTR correctors for the treatment of cystic fibrosis.
    Barreca M; Renda M; Spanò V; Montalbano A; Raimondi MV; Giuffrida S; Bivacqua R; Bandiera T; Galietta LJV; Barraja P
    Eur J Med Chem; 2024 Oct; 276():116691. PubMed ID: 39089001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Airway Epithelial Inflammation
    Gentzsch M; Cholon DM; Quinney NL; Martino MEB; Minges JT; Boyles SE; Guhr Lee TN; Esther CR; Ribeiro CMP
    Front Pharmacol; 2021; 12():628722. PubMed ID: 33859562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of the mechanism of action of RDR01752, a novel corrector of F508del-CFTR.
    Lopes-Pacheco M; Silva IAL; Turner MJ; Carlile GW; Sondo E; Thomas DY; Pedemonte N; Hanrahan JW; Amaral MD
    Biochem Pharmacol; 2020 Oct; 180():114133. PubMed ID: 32628927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Searching for combinations of small-molecule correctors to restore f508del-cystic fibrosis transmembrane conductance regulator function and processing.
    Boinot C; Jollivet Souchet M; Ferru-Clément R; Becq F
    J Pharmacol Exp Ther; 2014 Sep; 350(3):624-34. PubMed ID: 24970923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of novel F508del-CFTR traffic correctors among triazole derivatives.
    Bacalhau M; Ferreira FC; Kmit A; Souza FR; da Silva VD; Pimentel AS; Amaral MD; Buarque CD; Lopes-Pacheco M
    Eur J Pharmacol; 2023 Jan; 938():175396. PubMed ID: 36410419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of novel VX-809 hybrid derivatives as F508del-CFTR correctors by molecular modeling, chemical synthesis and biological assays.
    Parodi A; Righetti G; Pesce E; Salis A; Tasso B; Urbinati C; Tomati V; Damonte G; Rusnati M; Pedemonte N; Cichero E; Millo E
    Eur J Med Chem; 2020 Dec; 208():112833. PubMed ID: 32971410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correctors of the Major Cystic Fibrosis Mutant Interact through Membrane-Spanning Domains.
    Laselva O; Molinski S; Casavola V; Bear CE
    Mol Pharmacol; 2018 Jun; 93(6):612-618. PubMed ID: 29618585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rescue of Mutant CFTR Trafficking Defect by the Investigational Compound MCG1516A.
    Lopes-Pacheco M; Bacalhau M; Ramalho SS; Silva IAL; Ferreira FC; Carlile GW; Thomas DY; Farinha CM; Hanrahan JW; Amaral MD
    Cells; 2022 Jan; 11(1):. PubMed ID: 35011698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pseudomonas aeruginosa Reduces VX-809 Stimulated F508del-CFTR Chloride Secretion by Airway Epithelial Cells.
    Stanton BA; Coutermarsh B; Barnaby R; Hogan D
    PLoS One; 2015; 10(5):e0127742. PubMed ID: 26018799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of Polarized Cystic Fibrosis Airway Cells With HGF Prevents VX-661-Rescued F508del-CFTR Destabilization Caused by Prolonged Co-exposure to VX-770.
    Matos AM; Jordan P; Matos P
    Front Mol Biosci; 2021; 8():812101. PubMed ID: 35004859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The investigational Cystic Fibrosis drug Trimethylangelicin directly modulates CFTR by stabilizing the first membrane-spanning domain.
    Laselva O; Molinski S; Casavola V; Bear CE
    Biochem Pharmacol; 2016 Nov; 119():85-92. PubMed ID: 27614011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Revertants, low temperature, and correctors reveal the mechanism of F508del-CFTR rescue by VX-809 and suggest multiple agents for full correction.
    Farinha CM; King-Underwood J; Sousa M; Correia AR; Henriques BJ; Roxo-Rosa M; Da Paula AC; Williams J; Hirst S; Gomes CM; Amaral MD
    Chem Biol; 2013 Jul; 20(7):943-55. PubMed ID: 23890012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A synonymous codon change alters the drug sensitivity of ΔF508 cystic fibrosis transmembrane conductance regulator.
    Bali V; Lazrak A; Guroji P; Fu L; Matalon S; Bebok Z
    FASEB J; 2016 Jan; 30(1):201-13. PubMed ID: 26336913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review.
    Yang H; Ma T
    Expert Opin Ther Pat; 2015; 25(9):991-1002. PubMed ID: 25971311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Journey on VX-809-Based Hybrid Derivatives towards Drug-like F508del-CFTR Correctors: From Molecular Modeling to Chemical Synthesis and Biological Assays.
    Parodi A; Righetti G; Pesce E; Salis A; Tomati V; Pastorino C; Tasso B; Benvenuti M; Damonte G; Pedemonte N; Cichero E; Millo E
    Pharmaceuticals (Basel); 2022 Feb; 15(3):. PubMed ID: 35337072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Capturing the Direct Binding of CFTR Correctors to CFTR by Using Click Chemistry.
    Sinha C; Zhang W; Moon CS; Actis M; Yarlagadda S; Arora K; Woodroofe K; Clancy JP; Lin S; Ziady AG; Frizzell R; Fujii N; Naren AP
    Chembiochem; 2015 Sep; 16(14):2017-22. PubMed ID: 26227551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Corrector VX-809 stabilizes the first transmembrane domain of CFTR.
    Loo TW; Bartlett MC; Clarke DM
    Biochem Pharmacol; 2013 Sep; 86(5):612-9. PubMed ID: 23835419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of the cystic fibrosis mutation F508del-CFTR on renal cyst formation and growth.
    Li H; Yang W; Mendes F; Amaral MD; Sheppard DN
    Am J Physiol Renal Physiol; 2012 Oct; 303(8):F1176-86. PubMed ID: 22874761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.